Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02068794 · ClinicalTrials.gov registry record · Phase 1
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
A Phase 1 study of Ovarian Endometrioid Adenocarcinoma and Fallopian Tube Endometrioid Adenocarcinoma, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT02068794 is a Phase 1 study of Ovarian Endometrioid Adenocarcinoma and Fallopian Tube Endometrioid Adenocarcinoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 34 participants, below the 300-participant average among 15 other Ovarian Endometrioid Adenocarcinoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02068794, a Phase 1 study of Ovarian Endometrioid Adenocarcinoma and Fallopian Tube Endometrioid Adenocarcinoma, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II trial studies the side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to see how well it works in treating patients with ovarian, primary peritoneal or fallopian tube cancer that has come back. Mesenchymal stem cells may be able to carry tumor-killing substances directly to ovarian, primary peritoneal and fallopian tube cancer cells.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Echocardiography
- PROCEDURE Multigated Acquisition Scan
- PROCEDURE Mesenchymal Stem Cell Transplantation
- BIOLOGICAL Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2014-04-25 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02068794
The ClinicalTrials.gov registry entry for NCT02068794 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 300-participant average among 15 other Ovarian Endometrioid Adenocarcinoma trials with a reported enrollment target (89% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Ovarian Endometrioid Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02068794 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02068794 about?
NCT02068794 is a clinical study titled "MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer". This phase I/II trial studies the side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to see how well it works in treating patients with ovarian, primary peritoneal or fallopian tube cancer that has come back. ...
What is the current status of trial NCT02068794?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2014-04-25. Estimated completion is 2026-09-01.
What conditions does trial NCT02068794 study?
This clinical trial studies the following conditions: Ovarian Endometrioid Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma.
What interventions are being tested in trial NCT02068794?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Echocardiography (PROCEDURE), Multigated Acquisition Scan (PROCEDURE), Mesenchymal Stem Cell Transplantation (PROCEDURE), Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter (BIOLOGICAL).
Who is sponsoring clinical trial NCT02068794?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02068794 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Endometrioid Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
RECRUITING · Early Phase 1
-
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
RECRUITING · Phase 3
Explore more on PlainTrial
Ovarian Endometrioid Adenocarcinoma
All registered trials for this condition
Fallopian Tube Endometrioid Adenocarcinoma
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.